Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
|
31733575 |
2020 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer.
|
31403177 |
2020 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer.
|
31755998 |
2020 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study reaffirms the importance of PR in mediating MPA action in an endogenous breast cancer context where multiple steroid receptors are co-expressed and has potential implications for PR-targeting therapeutic strategies in ER+ breast cancer.
|
31805393 |
2019 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the progesterone receptor (PgR) is also a prognostic factor for ER-positive breast cancer, the PgR status was not considered a prognostic factor in the original PEPI scoring system.
|
30080878 |
2018 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Progesterone receptor and Ki67 expressions were assessed by dual-fluorescence immunohistochemistry in estrogen-receptor-positive breast cancer tissues.
|
30841783 |
2018 |
Oestrogen receptor positive breast cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that miR-181a, miR-23a and miR-26b act as negative regulators of PR expression in ER-positive breast cancer.
|
28404930 |
2017 |
Oestrogen receptor positive breast cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the clinical characteristics and prognosis of ER positive breast cancer with different PR expression levels.
|
28690652 |
2017 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our review will focus on the established and emerging clinical evidence for activating PR or AR in ER-positive breast cancer to inhibit the tumour growth-promoting functions of ER.
|
27729416 |
2016 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of the progesterone receptor (PR) isoform A (PR-A) is a negative prognosticator for estrogen receptor (ER)-positive breast cancer but in vitro studies have implicated PR-B in progestin-induced invasiveness.
|
26356672 |
2015 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most significantly associated genes were GHRH, CALM2, CETP, and AKR1C1 for overall breast cancer (gene-based nominal p ≤ 0.01); NR0B1, IGF2R, CALM2, CYP1B1, and GRB2 for ER+ breast cancer (p ≤ 0.02); and PGR, MAPK3, MAP3K1, and LHCGR for ER- disease (p ≤ 0.02).
|
26458823 |
2015 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the other hand, the clinical role of progesterone receptor (PgR) in ER-positive breast cancer remains controversial, although testing of PgR by immunohistochemistry (IHC) has become routine.
|
24549642 |
2014 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Absence of PR expression should be re-evaluated as a biomarker for poor prognosis in ER-positive breast cancer and such patients considered for additional systemic therapy.
|
24300977 |
2014 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a genome-wide analysis, progesterone receptor was among the least variable genes in ER- breast cancer.
|
23971947 |
2013 |
Oestrogen receptor positive breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 OR, 1.10; 95% confidence interval (CI), 1.05-1.15; P = 3.49 × 10(-5)] and triple-negative (ER-, PR-, and HER2-negative) breast cancer (rs8170: OR, 1.22; 95% CI, 1.13-1.31; P = 2.22 × 10(-7)).
|
22331459 |
2012 |
Oestrogen receptor positive breast cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PATIENTS AND METHODS Expression of Ki67, HER2, and PR was measured by immunohistochemistry in tumor samples from 798 patients with ER-positive breast cancer who participated in PACS01, a randomized trial that evaluated the efficacy of docetaxel.
|
19380452 |
2009 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oxidative stress can modify estrogen receptor (ER) structure and function, including induction of progesterone receptor (PR), altering the biology and clinical behavior of endocrine responsive (ER-positive) breast cancer.
|
18631401 |
2008 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of progesterone receptor (PR) in estrogen receptor (ER)-positive breast cancer is associated with a good prognosis, and indicates that tumors are likely to respond to tamoxifen.
|
16645950 |
2006 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In oestrogen receptor-positive (ER+) breast cancer, HER-2/neu and the progesterone receptor (PR) are inversely associated.
|
15868434 |
2005 |
Oestrogen receptor positive breast cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data paralleled those seen in some in vivo studies showing a relationship between PR and ERbeta expression as well as ERbeta expression and tamoxifen sensitivity of ER-positive breast cancer patients.
|
15821116 |
2005 |